Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes

Next Previous
X
Search
Trial Profile

Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dapagliflozin/metformin (Primary) ; Saxagliptin (Primary) ; Glimepiride; Metformin; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms TRIPLE-AXEL study

    • Most Recent Events

    • 01 Sep 2024 Results published in the Diabetes, Obesity and Metabolism
    • 06 Oct 2023 Status changed from not yet recruiting to completed, according to results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
    • 06 Oct 2023 Primary endpoint (Proportion of patients who met HbA1c 6.5% without hypoglycaemia, weight gain, or discontinuation due to adverse events at 104 weeks) has been met, according to results presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top